Watch CSBR. Know when insiders buy.
One email the day a filing lands. Free.
CSBR
CHAMPIONS ONCOLOGY, INC.
5.10
+0.09 +1.80%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
57
WATCH · shorts 57
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $70.9MP/E —DIV YIELD —FCF YIELD -7.11%REV TTM $59.4M +4.4%NET INCOME −$1.1M −123.7%NET CASH —52W 4.92 – 8.30SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Apr 30derived | $13.8M | +12.0% | 50.8% | −$522K | −$667K | — | -0.04 | −$2M | $239K | −$2.2M | Jul 27 |
| Q3 2026 · Jan 31 | $16.6M | −2.8% | 46.7% | −$276K | −$279K | −106.2% | -0.02 | −$1.3M | $37K | −$1.4M | Mar 12 |
| Q2 2026 · Oct 31 | $15M | +11.5% | 51.7% | $185K | $268K | −63.2% | 0.02 | −$1.7M | $242K | −$2M | Dec 15 |
| Q1 2026 · Jul 31 | $14M | −0.5% | 42.9% | −$527K | −$436K | −133.2% | -0.03 | $600K | $46K | $554K | Sep 15 |
| Q4 2025 · Apr 30derived | $12.4M | −11.8% | 41.1% | −$2M | −$1.8M | — | -0.13 | $6.9M | $253K | $6.6M | Jul 27 |
| Q3 2025 · Jan 31 | $17M | +41.8% | 61.2% | $4.5M | $4.5M | — | 0.31 | $490K | $42K | $448K | Mar 12 |
| Q2 2025 · Oct 31 | $13.5M | +16.6% | 44.9% | $732K | $728K | — | 0.05 | −$283K | $94K | −$377K | Dec 15 |
| Q1 2025 · Jul 31 | $14.1M | +11.9% | 49.7% | $1.3M | $1.3M | — | 0.09 | $311K | $0 | $311K | Sep 15 |
| Q4 2024 · Apr 30derived | $14M | — | 48.2% | −$271K | −$109K | — | -0.01 | −$1.8M | −$3K | −$1.8M | Jul 23 |
| Q3 2024 · Jan 31 | $12M | — | 34.7% | −$2.6M | −$2.5M | — | -0.19 | −$919K | $92K | −$1M | Mar 17 |
| Q2 2024 · Oct 31 | $11.6M | — | 42.8% | −$2M | −$2.1M | — | -0.15 | $589K | $79K | $510K | Mar 17 |
| Q1 2024 · Jul 31 | $12.6M | — | 38.8% | −$2.6M | −$2.6M | — | -0.19 | −$4M | $668K | −$4.7M | Mar 17 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Apr 30 | $59.4M | 48.0% | −$1.1M | −$1.2M | -2.0% | -0.08 | −$4.5M | $564K | −$5M | — | — |
| FY2025 · to Apr 30 | $56.9M | 50.1% | $4.6M | $4.7M | 8.3% | 0.33 | $7.4M | $389K | $7M | $0 | — |
| FY2024 · to Apr 30 | $50.2M | 41.4% | −$7.4M | −$7.3M | -14.5% | -0.54 | −$6.1M | $836K | −$7M | $634K | — |
| FY2023 · to Apr 30 | $53.9M | 45.2% | −$5.3M | −$5.3M | -9.9% | -0.39 | $4M | $2.9M | $1.1M | $74K | — |
| FY2022 · to Apr 30 | $49.1M | 51.9% | $607K | $548K | 1.1% | 0.04 | $6.5M | $2.4M | $4.1M | $0 | — |
| FY2021 · to Apr 30 | $41M | 47.7% | $366K | $362K | 0.9% | 0.02 | −$1.7M | $3.3M | −$5M | — | — |
Every number comes from CHAMPIONS ONCOLOGY, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.